Latest / The Dales Report | Trade to Black
MindMed Soars Off Data and Its Impact on Psychedelics
On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to explore MindMed's groundbreaking announcement from their Phase 2B trial. Take a look into the implications of MindMed's compelling data for anxiety treatments and the broader industry, highlighting the transformative potential of psychedelics in mental health innovation. #NuminusWellness #PsychedelicTherapy #mindmed Have you subscribed to the Baked In Newsletter? 📜 Join 20k+ unfiltered investing elites. Get Baked In delivered to your inbox for free, 5…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.